Peptide Initiative

Peptides · Peptide comparison

Buserelin vs Triptorelin

A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeBuserelin200–200 mcgTriptorelin11.25–11.25 mg
FrequencyBuserelinOnce dailyTriptorelinOnce daily
AdministrationBuserelinSubcutaneous injectionTriptorelinIntramuscular injection
Cycle lengthBuserelinOngoing/indefiniteTriptorelinOngoing/indefinite
Onset speedBuserelinModerate (1-2 weeks)TriptorelinModerate (1-2 weeks)
Evidence levelBuserelinStrong human trials (Phase 3 or FDA approved)TriptorelinStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Hormone Suppression

Buserelin90%
TriptorelinNo recorded rating

Cancer Management

Buserelin86%
Triptorelin90%

Fertility Support

Buserelin83%
TriptorelinNo recorded rating

Hormone Regulation

BuserelinNo recorded rating
Triptorelin94%

Endometriosis Relief

BuserelinNo recorded rating
Triptorelin87%

Technical data

Compound specifications

Buserelin

Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6

Triptorelin

Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4

Protocols

Dosing compared

Buserelin

Subcutaneous

  • 500 mcgEvery 8 hours (3 times daily) · First 7 daysThe product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
  • 200 mcgOnce daily · Ongoing maintenanceAfter the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].

Intranasal

  • 400 mcg (2 sprays per nostril)3 times daily (1,200 mcg/day) · Ongoing maintenanceThe nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].

Implant

  • 6.3 mgOnce every 2 months · Long-termA long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
  • 9.45 mgOnce every 3 months · Long-termA larger implant lasts about 3 months between placements [5].

Triptorelin

Intramuscular injection

  • 3.75 mgOnce every 4 weeks · Ongoing while indicatedFDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
  • 11.25 mgOnce every 12 weeks · Ongoing while indicatedFDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
  • 22.5 mgOnce every 24 weeks · Ongoing while indicatedFDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].

Applications

Best suited for

Buserelin

Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Triptorelin

Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Research status

Safety & evidence

Buserelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved; no buserelin application in Drugs@FDA. Approved in Canada as SUPREFACT for advanced prostate cancer (injection and nasal solution) and endometriosis (nasal solution).
Safety overview
Buserelin is a GnRH agonist approved in Canada and Europe (not in the US), with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.

Contraindications

  • Pregnancy or breastfeeding
  • Hypersensitivity to GnRH agonists
  • Certain bone diseases when long-term use is planned

Triptorelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

  • Pregnancy (can affect fetal development)
  • Undiagnosed vaginal bleeding
  • Known hypersensitivity to GnRH agonists
  • Severe untreated depression
  • Active spinal cord compression in prostate cancer (requires urgent decompression)

Decision guide

Which is right for you?

Buserelin

Choose Buserelin if…

  • Managing advanced prostate cancer
  • Treating endometriosis and reducing associated pain
  • Optimizing ovarian response during fertility treatments

Triptorelin

Choose Triptorelin if…

  • Managing advanced prostate cancer when combined with other treatments
  • Relieving severe endometriosis pain and symptoms
  • Delaying puberty development in children with early sexual maturation